MEDICAL News & Analysis

Morningstar analyst Shane Ponraj discusses the latest clinical trial results from Eli Lilly.

Despite advancing from its October low, the undervalued stock of this narrow-moat company may have more room to run.

Mark LaMonica, CFA hosts Adrian Atkins (Senior Equity Analyst - covering utilities, transports and REITs including AGL Energy and Transurban) and...

Analysts say the incident has given the medical device company a 'rare opportunity’ to expand its market share.

Covid's winners and losers are returning to their prior trajectories. 

A return to normal has increased the incidence of burns and that means business for the spray-on-skin maker.

The single-product company is high-risk, high-reward.

Morningstar is looking past the reported net loss to increased use of the company’s flagship spray-on skin therapy.

The company’s revolutionary RECELL system is set to become a standard treatment and boost market share, says Nicolette Quinn.

Offloading its medical centre and dental business will allow the healthcare company to pay down debt and focus on the turnaround of other units